Reports
Sale
Global Tinea Corporis Treatment Market Share, Size, Forecast: By Drug Class: Antifungal, Steroids, Anti-Infectives, Others; By Route of Administration: Topical, Oral; By Distribution Channel: Drug Stores, Hospital Pharmacies, Online, Others; Regional Analysis; Market Dynamics: SWOT Analysis; Competitive Landscape; 2024-2032
Global Tinea Corporis Treatment Market Outlook
The global tinea corporis treatment market is being aided by the growing antifungal drugs market, which reached a value of about USD 17.48 billion in 2023. The antifungal drugs market is further expected to grow at a CAGR of 3% in the forecast period of 2024-2032 to reach a value of approximately USD 22.69 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Increasing Demand for Antifungals to Augment the Tinea Corporis Treatment Industry Growth
Based on drug class, the antifungal segment accounts for a significant share in the tinea corporis treatment industry. This can be attributed to their highly-effective nature. Moreover, they are the only viable option as far as the treatment of fungal diseases is concerned. Furthermore, a key reason for the dominance of the antifungal segment is the availability of numerous ways of using them. For instance, antifungal treatment is available in the form of drugs, creams, shampoos, and others. Additionally, the ease with which the customer can buy these antifungals plays a major role in the success of this segment.
North America to Provide Enhanced Growth Opportunities to the Tinea Corporis Treatment Industry
Region-wise, North America is expected to witness a robust growth over the forecast period owing to the new product innovations by companies in the region. Moreover, the producers are focusing more on the countries with high humidity levels owing to the higher ratio of occurrences of fungal infections in the region. Furthermore, greater awareness about fungal infections due to frequent medical conferences is a key factor in driving the market in the continent.
Tinea Corporis Treatment: Market Segmentation
Tinea corporis, more commonly known as ringworm, is a fungal infection of the legs and arms. Tinea corporis often spreads to other infected sites. It causes inflammation and itching and may even cause pustules. Tinea corporis is treated with the use of antifungal medicines like terbinafine.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By drug class, the market is divided into:
- Antifungal
- Steroids
- Anti-Infectives
- Others
Based on route of administration, the industry can be segmented into:
- Topical
- Oral
The market is divided based on distribution channel into:
- Drug Stores
- Hospital Pharmacies
- Online
- Others
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Increasing Usage and Entry of New Products to Bolster the Growth of the Tinea Corporis Treatment Industry
The tinea corporis treatment industry is expected to enjoy a significant growth in the upcoming years owing to the increasing usage of the existing products as well as the entry of new and refined products. The rising incidences of fungal diseases worldwide are anticipated to drive the tinea corporis treatment industry. The pharmaceutical giants globally are shifting their focus towards developing nations of the world to run their operations of the tinea corporis treatment industry. This can be attributed to the flexible FDI policies in these regions with preferences of the customers leaning towards the maintenance of aesthetic appearance.
Over the forecast period, the increasing tendency of households to pet an animal is anticipated to cause a surge in the market growth rate owing to the increased risk of getting infected with fungal diseases in the presence of an animal.
Key Industry Players in the Global Tinea Corporis Treatment Market
The report gives a detailed analysis of the following key players in the global tinea corporis treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- GlaxoSmithKline plc
- Glenmark Pharmaceuticals Limited
- Bayer AG
- Taro Pharmaceutical Industries Ltd.
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Tinea Corporis Treatment Market Analysis
8.1 Key Industry Highlights
8.2 Global Tinea Corporis Treatment Historical Market (2018-2023)
8.3 Global Tinea Corporis Treatment Market Forecast (2024-2032)
8.4 Global Tinea Corporis Treatment Market by Drug Class
8.4.1 Antifungal
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Steroids
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.4.3 Anti-Infectives
8.4.3.1 Historical Trend (2018-2023)
8.4.3.2 Forecast Trend (2024-2032)
8.4.4 Others
8.5 Global Tinea Corporis Treatment Market by Route of Administration
8.5.1 Topical
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 Oral
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.6 Global Tinea Corporis Treatment Market by Distribution Channel
8.6.1 Drug Stores
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Hospital Pharmacies
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.6.3 Online
8.6.3.1 Historical Trend (2018-2023)
8.6.3.2 Forecast Trend (2024-2032)
8.6.4 Others
8.7 Global Tinea Corporis Treatment Market by Region
8.7.1 North America
8.7.2 Europe
8.7.3 Asia Pacific
8.7.4 Latin America
8.7.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2018-2023)
9.3.2 Forecast Trend (2024-2032)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2018-2023)
9.4.2 Forecast Trend (2024-2032)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2018-2023)
9.5.2 Forecast Trend (2024-2032)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 GlaxoSmithKline plc
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Glenmark Pharmaceuticals Limited
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Bayer AG
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Taro Pharmaceutical Industries Ltd.
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 Others
13 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Tinea Corporis Treatment Market: Key Industry Highlights, 2018 and 2032
2. Global Tinea Corporis Treatment Historical Market: Breakup by Drug Class (USD Billion), 2018-2023
3. Global Tinea Corporis Treatment Market Forecast: Breakup by Drug Class (USD Billion), 2024-2032
4. Global Tinea Corporis Treatment Historical Market: Breakup by Route of Administration (USD Billion), 2018-2023
5. Global Tinea Corporis Treatment Market Forecast: Breakup by Route of Administration (USD Billion), 2024-2032
6. Global Tinea Corporis Treatment Historical Market: Breakup by Distribution Channel (USD Billion), 2018-2023
7. Global Tinea Corporis Treatment Market Forecast: Breakup by Distribution Channel (USD Billion), 2024-2032
8. Global Tinea Corporis Treatment Historical Market: Breakup by Region (USD Billion), 2018-2023
9. Global Tinea Corporis Treatment Market Forecast: Breakup by Region (USD Billion), 2024-2032
10. North America Tinea Corporis Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
11. North America Tinea Corporis Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
12. Europe Tinea Corporis Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
13. Europe Tinea Corporis Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
14. Asia Pacific Tinea Corporis Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
15. Asia Pacific Tinea Corporis Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
16. Latin America Tinea Corporis Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
17. Latin America Tinea Corporis Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
18. Middle East and Africa Tinea Corporis Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
19. Middle East and Africa Tinea Corporis Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
20. Global Tinea Corporis Treatment Market Structure
Key Questions Answered in the Report
In 2023, the global tinea corporis treatment market attained a value of nearly USD 17.48 billion.
The market is projected to grow at a CAGR of 3% between 2024 and 2032.
The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach USD 22.69 billion by 2032.
The major drivers of the industry include rising incomes, growing focus towards developing countries and increasing tendency of households to pet an animal.
The rising incidences of fungal diseases worldwide is expected to be a key trend guiding the growth of the industry.
The drug classes of tinea corporis treatment available are antifungal, steroids, and anti-infectives, amongst others.
Tinea corporis treatment can be administered through topical and oral routes.
Tinea corporis treatment can have different end-uses like drug stores, hospital pharmacies, and online, amongst others.
The leading players in this market are GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, and Bayer AG, Taro Pharmaceutical Industries Ltd., amongst others.
Analyst Review
The global tinea corporis treatment market attained a value of USD 17.48 billion in 2023, driven by rising incomes, growing focus towards developing countries and increasing tendency of households to pet an animal. Aided by the rising incidences of fungal diseases worldwide, the market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 3%. The market is projected to reach USD 22.69 billion by 2032.
EMR’s meticulous research methodology delves deep into the industry, covering the macro and micro aspects of the industry. Based on the drug classes, the tinea corporis treatment market can be segmented into antifungal, steroids, and anti-infectives, amongst others. By routes of administration, the industry can be divided into topical and oral. Tinea corporis treatment can have different end-uses like drug stores, hospital pharmacies, and online, amongst others. The key players in the above industry include GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, and Bayer AG, Taro Pharmaceutical Industries Ltd., amongst others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER